Anbio Biotechnology (NNNN) Stock Price & Analysis
Anbio Biotechnology (NNNN) closed at USD 3.3 on Thursday, October 15, 2026, down 7.56% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 3.57; the Oct 15, 2026 session ranged USD 3.09–3.7 on volume of 69,697 shares. Market capitalization is $144.84M, with a 52-week range of USD 3.09–44.73 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/NNNN.md
Key facts (NNNN)
- Analysts: None.
- Total return with dividends: 1Y -88.1% vs S&P 500 +18.1%; 5Y -42.8% vs S&P 500 +85.1%.
Analysts (NNNN)
Consensus None.
Total return (dividends reinvested) (NNNN)
| 1Y (from 2025-10-16) | 5Y (from 2025-02-17) | |
|---|---|---|
| Total return | -88.1% | -42.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -88.2% | -28.6% |
| Volatility (annualized) | 136.2% | 132.5% |
| Max drawdown | -92.0% (Jan 2026→Oct 2026) | -93.5% (Aug 2025→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 3.3 |
|---|---|
| Change | ▼ 7.56% (down) |
| Previous Close | USD 3.57 |
| Open | USD 3.63 |
| Day Range | USD 3.09 – 3.7 |
| 52-Week Range | USD 3.09 – 44.73 |
| Volume | 69,697 shares |
| Market Cap | $144.84M |
| Exchange | NGM |
Technical Analysis (NNNN)
Nexqual's technical model rates NNNN "SELL" based on 3 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 15.4 (oversold) |
| vs SMA50 | Below (USD 6.71) |
| MACD | -0.84 (negative) |
Analyst Ratings (NNNN)
Wall Street analysts rate NNNN "None", per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | None |
|---|
Earnings (NNNN)
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (NNNN)
| Total Revenue | $8.65M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +73.90% |
| Gross Margin | +87.24% |
| Operating Margin | +59.09% |
| Profit Margin | +74.06% |
| ROE | +27.05% |
| Current Ratio | 344.31 |
| Total Cash | $11.90M |
| Total Debt | $0 |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (NNNN)
Nexqual rates Anbio Biotechnology's overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Strong — Revenue +74% YoY (latest Q) |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $12M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$7M (TTM) |
| Efficiency | Strong — ROE 27%, ROA 14.7% |
Ownership (NNNN)
| Insider Ownership | +4.78% |
|---|---|
| Institutional Ownership | +5.01% |
| Shares Outstanding | 43.89M |
| Float | 39.69M |
| Short % of Float | +0.12% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (NNNN)
Anbio Biotechnology is led by Michael Lau (age 43), Chief Executive Officer, per Nexqual as of October 16, 2026 at 05:21 UTC.
| Chief Executive Officer | Michael Lau (age 43) |
|---|---|
| Chief Financial Officer | Suki Song (age 42) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KMTS | Kestra Medical Technologies, Lt | USD 28.68 | ▲ 6.34% |
| XRAY | DENTSPLY SIRONA Inc. | USD 8.83 | ▲ 3.76% |
| LMAT | LeMaitre Vascular, Inc. | USD 83.16 | ▲ 1.97% |
| ATRC | AtriCure, Inc. | USD 57.78 | ▲ 1.6% |
| WRBY | Warby Parker Inc. | USD 24.59 | ▼ 7.28% |
| PLSE | Pulse Biosciences, Inc | USD 45.59 | ▼ 6.08% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt